

1 **Title: Characteristic variables of acute ischemic stroke categorized according to body**
2 **mass index classifications**

3 **Running Title: Acute Ischemic Stroke and Body Mass Index**

4 Joe Senda, MD, PhD^{1,2}; Yoshinobu Amakusa, MD^{1,3}; Tomoki Hirunagi, MD, PhD^{1,3}; Ruido
5 Ida, MD^{2,4}; Hidenori Muro, MD, PhD²; Takahito Otani, PhD⁵; Hiroko Nakagawa-Senda,
6 MD, PhD, MPH⁵; Takehiro Naito, MD, PhD⁶; Takenori Kato, MD, PhD⁶; Toshinori
7 Hasegawa, MD, PhD⁶; Katsuhiro Kawaguchi, MD, PhD⁷; and Masahisa Katsuno, MD,
8 PhD³.

9 ¹Department of Neurology, Komaki City Hospital, Komaki, Japan.
10 TEL: +81-568-76-4131.

11 ²Department of Rehabilitation, Komaki City Hospital, Komaki, Japan.
12 TEL: +81-568-76-4131.

13 ³Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya,
14 Japan. TEL: +81-52-744-2391.

15 ⁴Department of Rehabilitation Medicine, Nagoya City University Graduate School of
16 Medical Sciences, Nagoya, Japan. TEL: +81-52-853-8733.

17 ⁵Department of Public Health, Nagoya City University Graduate School of Medical
18 Sciences, Nagoya, Japan. TEL: +81-52-853-8176.

19 ⁶Department of Neurosurgery, Komaki City Hospital, Komaki, Japan.
20 TEL: +81-568-76-4131.

21 ⁷Department of Cardiology, Komaki City Hospital, Komaki, Japan.
22 TEL: +81-568-76-4131.

1 **Address correspondence to:**

2 Joe Senda, MD, PhD.

3 Department of Neurology and Rehabilitation, Komaki city hospital, 1-20 Jyoubushi

4 Komaki 485-8520, Japan. TEL: +81-568-76-4131.

5 E-mail: senda1@med.nagoya-u.ac.jp

6 **Other authors' E-mail address:**

7 Yoshinobu Amakusa: amakusa.med.758@gmail.com

8 Tomoki Hirunagi: to-hiru@hotmail.co.jp

9 Takahito Otani: otani@med.nagoya-cu.ac.jp

10 Hiroko Nakagawa-Senda: nakagawa@med.nagoya-cu.ac.jp

11 Ruido Ida: world21requiem@hotmail.com

12 Hidenori Muro: httmrcz@gmail.com

13 Takehiro Naito: tnaito2004@yahoo.co.jp

14 Takenori Kato: neuro.kato@gmail.com

15 Toshinori Hasegawa: h-toshi@komakihp.gr.jp

16 Katsuhiro Kawaguchi: kawa@komakihp.gr.jp

17 Masahisa Katsuno: ka2no@med.nagoya-u.ac.jp

18 **List of contents:** Abstract: 250 words, Text: 5948 words (including tables, figure legends,

19 and references), Title: 13 words / 106 characters, 1 figure, 2 tables, 40 references.

1 **Abstract**

2 **BACKGROUND:** We investigated the characteristic variables of acute ischemic stroke
3 categorized according to body mass index (BMI).

4 **METHODS:** From a registry of 1676 consecutive acute ischemic stroke cases, 965 cases
5 (622 men and 434 women; mean age 71.53 ± 12.42 years) were selected based on eligibility
6 criteria. These participants were divided into four cohorts according to BMI classifications:
7 BMI < 18 (underweight), $18.5 \leq \text{BMI} < 25$ (normal weight), $25 \leq \text{BMI} < 30$ (overweight),
8 and BMI ≥ 30 (obese). To avoid bias, propensity score analyses were performed; the
9 confounding variables of sex and age were adjusted.

10 **RESULTS:** The underweight cohort (n = 82) had an older, largely female population. The
11 overweight (n = 212) and obese cohorts (n = 48) had younger populations. The analyses
12 revealed no significant differences in neurological outcomes among the four cohorts.
13 Furthermore, higher risks of hyperlipidemia, dyslipidemia, and diabetes mellitus were
14 associated with the higher BMI cohorts in participants with acute ischemic stroke. Findings
15 revealed higher rates of usage of antidiabetic and antidyslipidemic medications in the
16 overweight cohort (p = 0.007, p = 0.003; respectively) and raised values of triglycerides,
17 low-density lipoprotein cholesterol, and glycated hemoglobin in the obese cohort (p = 0.044,
18 p = 0.019, p < 0.001; respectively) than in the normal weight cohort. By contrast, the lower
19 BMI cohort (underweight) did not have hyperlipidemia.

20 **CONCLUSIONS:** The importance of focusing on the management of dyslipidemia,
21 hyperlipidemia, and hyperglycemia for acute ischemic stroke in patients who are
22 overweight or obese has been highlighted.

- 1 **Key words:** Body Mass Index, dyslipidemias, hyperlipidemias, ischemic stroke,
- 2 overweight.

1 INTRODUCTION

2 Obesity is an important risk factor associated with a greater incidence of stroke ^{1,2}. Body
3 mass index (BMI) is widely used as an index of obesity derived from the variables of body
4 weight and height. ³. According to a previous meta-analysis ⁴, the risk of stroke is positively
5 correlated with BMI, and this correlation is stronger in men and patients with ischemic
6 stroke. The findings of yet another study supported this meta-analysis, revealing that the
7 BMI categories of overweight and obesity were associated with an increased risk only in
8 men ⁵. It has been shown that there is a positive correlation between the whole range of
9 BMI categories and ischemic stroke ⁶, with no evidence of a threshold or a J-shaped curve
10 ^{7,8}. Conversely, the BMI category of underweight in both sexes is also associated with a
11 higher risk of ischemic stroke, and this category has a significantly higher rate of poor short
12 and long-term outcomes than the BMI category of normal weight ^{9,10,11}. Other studies
13 regarding the association between BMI and the prognosis after acute ischemic stroke have
14 shown that BMI has a non-linear association with 3-month outcomes in men with acute
15 ischemic stroke ⁸, and that the BMI categories of underweight and obesity were generally
16 associated with poorer outcomes ^{12,13,14}.

17 The mechanisms of the nature in which BMI affects ischemic stroke are not fully
18 understood. However, possible explanations include an elevated BMI increasing the risk of
19 ischemic stroke by inducing hypertension, diabetes, dyslipidemia, and inflammation, which
20 are known risk factors for atherosclerosis and thrombosis ^{15,16}. These risk factors may
21 impair cerebral blood flow and oxygen delivery, leading to ischemic injury ¹⁶. By contrast,
22 a low BMI increases the risk of ischemic stroke through malnutrition, anemia, infection,

1 and immunosuppression, which may compromise the brain's resistance to ischemia. In
2 addition, a low BMI may increase the risk of hemorrhagic transformation after ischemic
3 stroke due to reduced clotting factors and platelets^{17,18}.

4 Some studies have shown that BMI exhibits an influence on the outcomes of ischemic
5 stroke^{19,20}. However, the precise correlation of the wide-ranged BMI classification,
6 including both categories of obesity and underweight, and characteristic variables of
7 ischemic stroke have not been fully elucidated.

8 In the present study, we investigated the categorization of the characteristic variables and
9 outcomes of the acute phase of ischemic stroke by BMI classifications in a single-center
10 study. Many of these variables were determined by various analyses, such as blood tests
11 and brain magnetic resonance imaging/angiography (MRI/MRA).

12

13 **METHODS**

14 *Ethical Approval and Informed Consent*

15 Informed consent was obtained from all study participants. This study was approved by
16 the Ethics Committee of the Komaki City Hospital (approval number: 231003), and was
17 performed in accordance with the provisions of the Declaration of Helsinki (as revised in
18 Brazil 2013).

19

20 *Enrolment of Participants*

21 We retrospectively registered 1676 consecutive cases of acute ischemic stroke that were
22 hospitalized at the Komaki City Hospital from 2018 to 2022. As depicted in Figure 1, a

1 total of 965 participants (622 men and 434 women, mean age 71.53 ± 12.42 years) were
2 enrolled in the study. The inclusion criteria were as follows: (1) complete independence in
3 performing ADLs, based on a score of 0 on the modified Rankin Scale in which the
4 participant lived alone prior to the current episode of ischemic stroke ²¹; (2) no previous
5 medical history of dementia, including Alzheimer's disease; mild cognitive impairment or
6 neurodegenerative diseases prior to the current ischemic stroke (this medical history was
7 determined from the case files and interviews with participants and their families); and (3)
8 participants who underwent brain MRI/MRA with the resultant diagnosis of the current
9 ischemic stroke. As a result, the following cases were excluded: (i) in-hospital mortalities,
10 due to missing data (n = 84); (ii) cases in which the participants had previous medical
11 histories of both ischemic and hemorrhagic stroke (n = 395), dementia (n = 139),
12 neurodegenerative diseases (n = 19); and (iii) cancer that was not in remission at the time of
13 the current ischemic stroke (n = 20). In addition, participants who had incomplete
14 independence in performing activities of daily living (ADLs) before the current ischemic
15 stroke secondary to conditions such as orthopedic impediments (n = 20) were excluded.
16 Finally, participants with missing data regarding their clinical examinations and
17 investigations, such as laboratory blood tests and imaging findings, were not included in the
18 statistical analysis (n = 34). The BMI, laboratory blood tests, and carotid ultrasounds were
19 measured on admission, and the National Institutes of Health Stroke Scale (NIHSS) scores
20 ²² were measured at discharge.

21

22 *Ischemic stroke subtype evaluation*

1 In addition to the clinical categories of the National Institute of Neurological Disorders
2 and Stroke-Classification of cerebrovascular diseases III of lacunar infarctions (LI),
3 atherothrombotic (AT), and cardioembolic (CE) strokes ²³, we appended artery-to-artery
4 (A-to-A) embolic infarctions. Based on the Trial of ORG 10172 in Acute Stroke Treatment
5 (TOAST) classification, A-to-A embolic infarctions that involve atheroembolic mechanisms
6 can be distinguished from LI, CE, and AT. Embolic cases in which A-to-A embolic
7 infarctions and CE strokes could not be diagnosed, or where the source of the embolism
8 was unknown were classified as: “embolic stroke of undetermined source (ESUS).”
9 Ischemic strokes secondary to a rare specific etiology, such as vasculitis or postoperative
10 ischemic stroke, were classified as: “stroke of other determined etiology.” ²⁴

11

12 *Analyses of MRI/MRA findings*

13 Brain MRI/MRA were performed in all 965 participants on admission to the Komaki City
14 Hospital. White matter lesions were classified using the Fazekas criteria for periventricular
15 hyperintensities (PVH) and deep white matter hyperintensities (DWMH) using
16 T2-weighted or fluid-attenuated inversion recovery images. PVH were graded from 0–3 as
17 follows: Grade 0 = absence or rim only, Grade 1 = localized lesion depicted as pencil-thin
18 lining or “caps”, Grade 2 = irregular hyperintensity with a smooth “halo”, and Grade 3 =
19 irregular lesion extending into the deep white matter and periventricular region ²⁵. DWMH
20 were graded from 0–3 as follows: Grade 0 = absence, Grade 1 = punctate foci, Grade 2 =
21 beginning confluence of foci, and Grade 3 = large confluent areas ²⁶. On MRA, “stenosis
22 positive” was defined as the presence of a stenosis or occlusion $\geq 50\%$ in the intracranial

1 trunk arteries within the visible range ²⁷.

2

3 *BMI categories*

4 We categorized the participants into four cohorts: underweight (Cohort 1), normal weight
5 (Cohort 2), overweight (Cohort 3), and obese (Cohort 4) defined as a BMI (kg/m²) of <
6 18.5, 18.5–24.9, 25.0–29.9, and ≥ 30, respectively ²⁸.

7

8 *Statistical analyses*

9 For the statistical analyses, continuous variables were presented as means ± standard
10 deviations. Categorical variables were presented as percentages. A chi-square test was
11 performed to compare categorical variables. A Steel-Dwass test was used for multiple
12 comparisons. A Mann-Whitney U-test for each two-cohort comparison was performed to
13 compare continuous variables. To avoid bias, confounding variables were balanced between
14 cohorts, and propensity score analyses were conducted in which the variables of sex and
15 age were adjusted for ²⁹. In the propensity score analyses, one-to-one nearest neighbor
16 matching without replacement was completed using a caliper width equal to 0.2 of the
17 standard deviation of the propensity score. After the propensity score analyses, the
18 comparisons among each of the four selected cohorts were conducted as follows: between
19 (1) underweight (Cohort 1) vs. normal weight (Cohort 2), (2) normal weight (Cohort 2) vs.
20 overweight (Cohort 3), (3) normal weight (Cohort 2) vs. obese (Cohort 4), and (4)
21 overweight (Cohort 3) vs. obese (Cohort 4). For all statistical analyses, data were analyzed
22 using EZR version 1.55 (Saitama Medical Center, Jichi Medical University, Saitama,

1 Japan)³⁰, which is a graphical user interface for R (The R Foundation for Statistical
2 Computing, version 4.1.2, Vienna, Austria; <http://cran.r-project.org/>). A p-value less than
3 0.05 was considered statistically significant.

4

5 **RESULTS**

6 *Demographic characteristics of participants categorized according to BMI classification*

7 The demographic characteristics of the study participants are summarized in Table 1.
8 Comparisons of demographic data among the four cohorts revealed statistically significant
9 differences in the variables of age and sex and other clinical indicators, such as hemoglobin
10 values, leukoaraiosis grades, dyslipidemia, diabetes mellitus, and NIHSS scores. In
11 particular, with age as a variable, the underweight cohort was statistically significantly
12 older than the normal-weight cohort ($p < 0.001$); however, the overweight and obesity
13 cohorts were statistically significantly younger than the normal weight cohort ($p < 0.001$).
14 Regarding sex as a variable, the underweight cohort had a statistically significant larger
15 number of women than that in the normal-weight cohort ($p < 0.001$). Furthermore, the
16 underweight and obesity cohorts had statistically significantly severer NIHSS scores than
17 those of the normal-weight cohort ($p = 0.003$, $p = 0.021$; respectively).

18

19 *Characteristics of the participants analyzed with propensity score matching methods*

20 A propensity score analysis was conducted to avoid bias due to the confounding variables
21 of age and sex. Table 2 depicts the characteristics of the participants as variables analyzed
22 with propensity score matching methods. Table 2 (a) reveals the results of the underweight

1 (Cohort 1) and normal weight (Cohort 2) cohorts after the propensity score analyses. These
2 results revealed that the values of the triglycerides (TG, $p = 0.013$) and glycosylated
3 hemoglobin (HbA1C, $p = 0.002$) in Cohort 1 were statistically significantly lower than
4 those in Cohort 2; however, the value of high-density lipoprotein cholesterol (HDL-C) in
5 Cohort 1 was statistically significantly higher than that in Cohort 2 ($p = 0.003$). Similarly,
6 Table 2 (b) reveals the results of the normal weight (Cohort 2) and overweight (Cohort 3)
7 cohorts and showed that the rates of the use of antihypertensive ($p < 0.001$), antidiabetic (p
8 $= 0.007$), and antidyslipidemic ($p = 0.003$) medications in Cohort 3 were statistically
9 significantly higher than those in Cohort 2. In addition, the values of hemoglobin (Hb) ($p <$
10 0.001), albumin ($p = 0.001$), TG ($p < 0.001$), and low-density lipoprotein cholesterol
11 (LDL-C) ($p = 0.004$) in Cohort 3 were statistically significantly higher than those in Cohort
12 2. Furthermore, the value of HDL-C ($p < 0.001$) in Cohort 3 was statistically significantly
13 lower than that in Cohort 2. Table 2 (c) reveals the results of the normal weight (Cohort 2)
14 and obese (Cohort 4) cohorts. These results showed that the rates of the use of antidiabetic
15 ($p < 0.001$) and disease type as atheroembolic ($p = 0.025$), as well as the values of Hb ($p =$
16 0.043), TG ($p = 0.044$), LDL-C ($p = 0.019$), and HBA1C ($p < 0.001$) in Cohort 4 were all
17 statistically significantly higher than those in Cohort 2. Table 2 (d) reveals the results of the
18 overweight (Cohort 3) and obese (Cohort 4) cohorts. There were no statistically significant
19 differences between the values of the clinical indicators for these two cohorts. Additionally,
20 regarding the NIHSS scores, the propensity score analyses revealed no statistically
21 significant differences among the four cohorts.

1 **DISCUSSION**

2 In the present study, each of the adverse outcomes (as determined by the NIHSS scores) of
3 acute ischemic stroke in the underweight and obese cohorts were statistically significantly
4 severer than those in the normal cohort. However, a propensity score analysis inclusive of
5 the variables of age and sex revealed no statistically significant difference in these adverse
6 outcomes among the four cohorts; thus, we hypothesized that these adverse outcomes were
7 strongly affected by the variables of age and sex ³¹.

8 In addition, we found statistically significant differences in hyperlipidemia and
9 dyslipidemia among the BMI cohorts. Previous literature reporting on the correlations
10 among BMI, hyperlipidemia, and ischemic stroke were based on cohort studies ^{27,32,33,34},
11 and there is little information regarding investigations performed at the acute phase of
12 ischemic stroke. The findings of the current study revealed that participants with acute
13 ischemic stroke in the overweight and obese cohorts had severe hyperlipidemia. These
14 cohorts had decreased values of HDL-C and increased values of LDL-C and TG; in
15 particular, the values of LDL-C and TG were severely increased in the obese cohort. In
16 addition, the elevated percentage values of HBA1C in the obese cohort were indicative of
17 diabetes mellitus. Previous studies have shown that patients with a high BMI also have
18 metabolic risk factors, including hyperlipidemia and diabetes mellitus ^{35,36,37}; therefore, we
19 postulate that these metabolic risk factors result in ischemic stroke occurring in relatively
20 younger patients.

21 By contrast, the underweight cohort did not have increased values of LDL-C and TG and
22 only had a statistically significantly increased HDL-C compared to the normal weight

1 cohort. The sarcopenia risk for stroke-associated infections is associated with a larger BMI
2 category of ≥ 18.5 ; thus, we hypothesize that the pathophysiological mechanisms of
3 ischemic stroke are different for our cohorts with larger BMIs^{15,16,38}. In addition, it is a
4 well-known fact that a larger body fat distribution, as indicated by an elevated BMI, has a
5 close relationship with the occurrence of metabolic disorders³⁹.

6 The present study has several limitations. First, this was not a population-based study;
7 patients were referred to this single acute care hospital that has a stroke unit. Second, we
8 could not further explore the data as per the stroke subtypes. Recent reports have revealed
9 that the overweight and obese BMI categories are inversely correlated with poor outcomes
10 of the cardioembolic and small vessel disease subtypes; however, there is no statistically
11 significant relationship between stroke outcomes and BMI classification for the large artery
12 disease subtypes⁴⁰. Furthermore, to firmly ratify conclusions, it must be considered that
13 these findings were observed in a relatively small population size. Therefore, further cohort
14 studies with larger population sizes are needed. Finally, this study may have been
15 influenced by unknown variables.

16 In conclusion, the findings of this current study revealed that higher risks of
17 hyperlipidemia, dyslipidemia, and diabetes mellitus were associated with the higher BMI
18 categories, viz., the overweight and obese cohorts, in participants with acute ischemic
19 stroke. This was evidenced by the higher rates of usage of antidiabetic and antidyslipidemic
20 medication in the overweight cohort, and the raised values of TG, LDL-C, and HBA1C in
21 the obese cohort than those in the normal weight cohort. By contrast, in participants with
22 acute ischemic stroke, the lower BMI category, viz., the underweight cohort, did not have

1 hyperlipidemia. Thus, our findings suggest that different pathophysiological mechanisms of
2 ischemic stroke may exist for higher BMIs. Furthermore, the importance of focusing on the
3 management of dyslipidemia, hyperlipidemia, and hyperglycemia for the acute phase of
4 ischemic stroke in patients who are overweight or obese has been highlighted. The
5 management and control of acute ischemic stroke related to BMI provides potentially
6 useful information to encourage further studies regarding the relationships between BMI,
7 metabolic risk factors, and the incidence of acute ischemic stroke.

8

9 **Acknowledgments**

10 We thank the staff of the Komaki City Hospital for collecting the data used in this study.

11

12 **Sources of Funding**

13 The authors state that they have no sources of funding.

14

15 **Conflicts of interest**

16 The authors state that they have no conflicts of interest.

1 **REFERENCES**

- 2 1. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of
3 co-morbidities related to obesity and overweight: a systematic review and meta-analysis.
4 *BMC Public Health*. 2009;9:88. doi: 10.1186/1471-2458-9-88
- 5 2. Qi W, Ma J, Guan T, Zhao D, Abu-Hanna A, Schut M, Chao B, Wang L, Liu Y. Risk
6 Factors for Incident Stroke and Its Subtypes in China: A Prospective Study. *J Am Heart*
7 *Assoc*. 2020;9:e016352. doi: 10.1161/JAHA.120.016352.
- 8 3. Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight and
9 obesity. *J Chronic Dis*. 1972;25:329-343. doi: 10.1016/0021-9681(72)90027-6.
- 10 4. Wang X, Huang Y, Chen Y, Yang T, Su W, Chen X, Yan F, Han L, Ma Y. The relationship
11 between body mass index and stroke: a systemic review and meta-analysis. *J Neurol*.
12 2022;269:6279-6289. doi: 10.1007/s00415-022-11318-1.
- 13 5. Shiozawa M, Kaneko H, Itoh H, Morita K, Okada A, Matsuoka S, Kiriyama H, Kamon T,
14 Fujiu K, Michihata N, et al. Association of Body Mass Index with Ischemic and
15 Hemorrhagic Stroke. *Nutrients*. 2021;13:2343. doi: 10.3390/nu13072343.
- 16 6. Song YM, Sung J, Davey Smith G, Ebrahim S. Body mass index and ischemic and
17 hemorrhagic stroke: a prospective study in Korean men. *Stroke*. 2004;35:831-836. doi:
18 10.1161/01.STR.0000119386.22691.1C.
- 19 7. Horn JW, Feng T, Mørkedal B, Aune D, Strand LB, Horn J, Mukamal KJ, Janszky I.
20 Body Mass Index Measured Repeatedly over 42 Years as a Risk Factor for Ischemic Stroke:
21 The HUNT Study. *Nutrients*. 2023;15:1232. doi: 10.3390/nu15051232.
- 22 8. Zan Y, Xiong W, Zhang X, Han Y, Cao C, Hu H, Wang Y, Ou H. Body mass index has a

- 1 non-linear association with three-month outcomes in men with acute ischemic stroke: An
2 analysis based on data from a prospective cohort study. *Front Endocrinol (Lausanne)*.
3 2022;13:1041379. doi: 10.3389/fendo.2022.1041379.
- 4 9. Jiang Y, Liu Z, Liao Y, Sun S, Dai Y, Tang Y. Ischemic stroke: From pathological
5 mechanisms to neuroprotective strategies. *Front Neurol*. 2022;13:1013083. doi:
6 10.3389/fneur.2022.1013083.
- 7 10. Chaudhary D, Khan A, Gupta M, Hu Y, Li J, Abedi V, Zand R. Obesity and mortality
8 after the first ischemic stroke: Is obesity paradox real? *PLoS One*. 2021;16:e0246877. doi:
9 10.1371/journal.pone.0246877.
- 10 11. Kawase S, Kowa H, Suto Y, Fukuda H, Kusumi M, Nakayasu H, Nakashima K.
11 Association between body mass index and outcome in Japanese ischemic stroke patients.
12 *Geriatr Gerontol Int*. 2017;17:369-374. doi: 10.1111/ggi.12713.
- 13 12. Song YM, Sung J, Davey Smith G, Ebrahim S. Body mass index and ischemic and
14 hemorrhagic stroke: a prospective study in Korean men. *Stroke*. 2004;35:831-836. doi:
15 10.1161/01.STR.0000119386.22691.1C.
- 16 13. Li X, Xu Q, Wang A, Zheng P, Zhu H, Guo A, Meng X, Jiang Y. Association of body
17 mass index and waist-to-height ratio with outcomes in ischemic stroke: results from the
18 Third China National Stroke Registry. *BMC Neurol*. 2023;23:152. doi:
19 10.1186/s12883-023-03165-y.
- 20 14. Elagizi A, Kachur S, Lavie CJ, Carbone S, Pandey A, Ortega FB, Milani RV. An
21 Overview and Update on Obesity and the Obesity Paradox in Cardiovascular Diseases.
22 *Prog Cardiovasc Dis*. 2018;61:142-150. doi: 10.1016/j.pcad.2018.07.003.

- 1 15. Jiang Y, Liu Z, Liao Y, Sun S, Dai Y, Tang Y. Ischemic stroke: From pathological
2 mechanisms to neuroprotective strategies. *Front Neurol.* 2022;13:1013083. doi:
3 10.3389/fneur.2022.1013083.
- 4 16. Park H, Lee HW, Yoo J, Lee HS, Nam HS, Kim YD, Heo JH. Body Mass Index and
5 Prognosis in Ischemic Stroke Patients With Type 2 Diabetes Mellitus. *Front Neurol.*
6 2019;10:563. doi: 10.3389/fneur.2019.00563.
- 7 17. Song X, Chen X, Bai J, Zhang J. Association between pre-stroke sarcopenia risk and
8 stroke-associated infection in older people with acute ischemic stroke. *Front Med*
9 *(Lausanne)*. 2023;10:1090829. doi: 10.3389/fmed.2023.1090829.
- 10 18. Bazzano LA, Gu D, Whelton MR, Wu X, Chen CS, Duan X, Chen J, Chen JC, He J.
11 Body mass index and risk of stroke among Chinese men and women. *Ann Neurol.*
12 2010;67:11-20. doi: 10.1002/ana.21950.
- 13 19. Liu X, Zhang D, Liu Y, Sun X, Hou Y, Wang B, Ren Y, Zhao Y, Han C, Cheng C, et al.
14 A J-shaped relation of BMI and stroke: Systematic review and dose-response meta-analysis
15 of 4.43 million participants. *Nutr Metab Cardiovasc Dis.* 2018;28:1092-1099. doi:
16 10.1016/j.numecd.2018.07.004.
- 17 20. Dicipinigaitis AJ, Palumbo KE, Gandhi CD, Cooper JB, Hanft S, Kamal H, Shapiro SD,
18 Feldstein E, Kafina M, Kurian C, et al. Association of Elevated Body Mass Index with
19 Functional Outcome and Mortality following Acute Ischemic Stroke: The Obesity Paradox
20 Revisited. *Cerebrovasc Dis.* 2022;51:565-569. doi: 10.1159/000521513.
- 21 21. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver
22 agreement for the assessment of handicap in stroke patients. *Stroke.* 1988;19:604-607. doi:

1 10.1161/01.str.19.5.604.

2 22. Goldstein LB, Samsa GP. Reliability of the National Institutes of Health Stroke Scale.
3 Extension to non-neurologists in the context of a clinical trial. *Stroke*. 1997;28:307-310.
4 doi: 10.1161/01.str.28.2.307.

5 23. Special report from the National Institute of Neurological Disorders and Stroke.
6 Classification of cerebrovascular disease III. *Stroke*. 1990;21:637-676.
7 doi:10.1161/01.str.21.4.637.

8 24. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd.
9 Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter
10 clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. *Stroke*. 1993;24:35-41.
11 doi: 10.1161/01.str.24.1.35.

12 25. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities
13 at 1.5 T in Alzheimer's dementia and normal aging. *AJNR Am J Roentgenol*.
14 1987;149:351-356. doi: 10.2214/ajr.149.2.351.

15 26. Fazekas F, Kleinert R, Offenbacher H, Payer F, Schmidt R, Kleinert G, Radner H,
16 Lechner H. The morphologic correlate of incidental punctate white matter hyperintensities
17 on MR images. *AJNR Am J Neuroradiol*. 1991;12:915-921.

18 27. Henninger N, Khan MA, Zhang J, Moonis M, Goddeau RP Jr. Leukoaraiosis predicts
19 cortical infarct volume after distal middle cerebral artery occlusion. *Stroke*.
20 2014;45:689-695. doi: 10.1161/STROKEAHA.113.002855.

21 28. Itoh H, Kaneko H, Kiriya H, Kamon T, Fujiu K, Morita K, Yotsumoto H, Michihata
22 N, Jo T, Takeda N, et al. Reverse J-shaped relationship between body mass index and

- 1 in-hospital mortality of patients hospitalized for heart failure in Japan. *Heart Vessels*.
2 2021;36:383-392. doi: 10.1007/s00380-020-01699-6.
- 3 29. Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the
4 application of propensity score methods yielded increasing use, advantages in specific
5 settings, but not substantially different estimates compared with conventional multivariable
6 methods. *J Clin Epidemiol*. 2006;59:437-447. doi: 10.1016/j.jclinepi.2005.07.004.
- 7 30. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical
8 statistics. *Bone Marrow Transplant*. 2013;48:452-458. Epub 2012/12/05. doi:
9 10.1038/bmt.2012.244.
- 10 31. Roy-O'Reilly M, McCullough LD. Age and Sex Are Critical Factors in Ischemic Stroke
11 Pathology. *Endocrinology*. 2018;159:3120-3131. doi: 10.1210/en.2018-00465.
- 12 32. Xu T, Zhang JT, Yang M, Zhang H, Liu WQ, Kong Y, Xu T, Zhang YH. Dyslipidemia
13 and outcome in patients with acute ischemic stroke. *Biomed Environ Sci*. 2014;27:106-110.
14 doi: 10.3967/bes2014.023.
- 15 33. Kawate N, Kayaba K, Hara M, Kotani K, Ishikawa S; Jichi Medical School Cohort
16 Study Group. Body mass index and stroke incidence in Japanese community residents: The
17 Jichi Medical School (JMS) Cohort Study. *J Epidemiol*. 2017;27:325-330. doi:
18 10.1016/j.je.2016.08.007.
- 19 34. Zhang P, Yan XL, Qu Y, Guo ZN, Yang Y. Association between abnormal body weight
20 and stroke outcome: A meta-analysis and systematic review. *Eur J Neurol*. 2021
21 Aug;28(8):2552-2564. doi: 10.1111/ene.14881.
- 22 35. Hu H, Hori A, Nishiura C, Sasaki N, Okazaki H, Nakagawa T, Honda T, Yamamoto S,

- 1 Tomita K, Miyamoto T, et al. HbA1c, Blood Pressure, and Lipid Control in People with
2 Diabetes: Japan Epidemiology Collaboration on Occupational Health Study. *PLoS One*.
3 2016;11:e0159071. doi: 10.1371/journal.pone.0159071.
- 4 36. Hori A, Nanri A, Sakamoto N, Kuwahara K, Nagahama S, Kato N, Fukasawa K,
5 Nakamoto K, Ohtsu M, Matsui A, et al. Comparison of body mass index, waist
6 circumference, and waist-to-height ratio for predicting the clustering of cardiometabolic
7 risk factors by age in Japanese workers--Japan Epidemiology Collaboration on
8 Occupational Health study. *Circ J*. 2014;78:1160-1168. doi: 10.1253/circj.cj-13-1067.
- 9 37. Matsushita Y, Tomita K, Yokoyama T, Mizoue T. Relations between waist
10 circumference at four sites and metabolic risk factors. *Obesity (Silver Spring)*.
11 2010;18:2374-2378. doi: 10.1038/oby.2010.33.
- 12 38. Scherbakov N, Sandek A, Doehner W: Stroke-related sarcopenia: specific
13 characteristics. *J Am Med Dir Assoc*. 2015;16:272-276. doi: 10.1016/j.jamda.2014.12.007.
- 14 39. Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the
15 Study of Obesity. New criteria for 'obesity disease' in Japan. *Circ J*. 2002 ;66:987-992. doi:
16 10.1253/circj.66.987.
- 17 40. Lee SH, Jung JM, Park MH. Obesity paradox and stroke outcomes according to stroke
18 subtype: a propensity score-matched analysis. *Int J Obes (Lond)*. 2023;47:669-676. doi:
19 10.1038/s41366-023-01318-0.

1 **Figure 1. Flowchart Depicting Enrolment of Participants**

2 Consecutive cases of acute ischemic stroke were registered at the Komaki City Hospital
3 database between January 2018 and December 2022 (n = 1676). We excluded mortalities (n
4 = 84). We also excluded participants who had previous medical histories of both ischemic
5 and hemorrhagic stroke (n = 395), dementia (n = 139), neurodegenerative diseases (n = 19),
6 and cancer that was not in remission at the time of the current ischemic stroke (n = 20).
7 In addition, participants who had incomplete independence in performing activities of daily
8 living (ADLs) before the current ischemic stroke secondary to conditions such as
9 orthopedic impediments (n = 20) were excluded. Participants with missing data regarding
10 their clinical examinations and investigations, such as laboratory blood tests and imaging
11 findings, were not included in the statistical analysis (n = 34). Finally, 965 participants were
12 included in the present study.

Table 1: Demographic characteristics of participants categorized according to body mass index classification

	All (n=965)	Cohort 1 (n=82)	Cohort 2 (n=623)	Cohort 3 (n=212)	Cohort 4 (n=48)	p-value Steel-Dwass test	p-value (post-hoc analysis as each two group comparison)			
		BMI<18.5	18.5≤BMI<25	25≤BMI<30	30≤BMI		Cohort 1 vs 2	Cohort 2 vs 3	Cohort 2 vs 4	Cohort 3 vs 4
Age (years)	71.53±12.42	78.91±9.93	72.81±11.42	68.42±12.31	55.95±13.39	<0.001†	<0.001†	<0.001†	<0.001†	<0.001†
Male /Female	622 / 343	37 / 45	413 / 210	140 / 72	32 / 16	0.002†	0.001†	0.999	0.999	0.999
Body Mass Index (kg/m ²)	23.29±3.87	17.10±1.34	22.14±1.71	26.85±1.36	33.01±4.34	<0.001†	<0.001†	<0.001†	<0.001†	<0.001†
Length of hospitalization (days)	16.79±12.92	21.96±18.24	16.64±12.42	15.88±12.21	13.81±8.85	0.001†	0.005†	0.941	0.600	0.779
Risk factor and comorbidity										
Current smoker, n (%)	218 (22.6%)	10 (12.2%)	135 (21.7%)	53 (25.0%)	20 (41.7%)	<0.001†	0.107	0.007†	0.999	0.321
History of heart disease†, n (%)	94 (9.7%)	6 (7.3%)	63 (10.1%)	22 (10.4%)	3 (6.3%)	0.002†	0.063	0.089	0.774	0.993
Current medication										
Hypertension, n (%)	663 (68.7%)	44 (53.7%)	421 (67.6%)	166 (78.3%)	32 (66.7%)	0.001†	0.190	0.748	0.084	0.094
Diabetes mellitus, n (%)	240 (24.9%)	13 (15.9%)	139 (22.3%)	66 (31.1%)	22 (45.8%)	<0.001†	0.554	0.049†	0.001†	0.211
Dyslipidemia, n (%)	445 (46.1%)	25 (30.5%)	280 (44.9%)	115 (54.2%)	25 (52.1%)	0.704	0.854	0.995	0.823	0.818
Ischemic stroke subtype										
Lacunar infarction, n (%)	125 (13.0%)	2 (2.4%)	75 (12.0%)	38 (17.9%)	10 (20.8%)	0.001†	0.043†	0.133	0.290	0.966
Atherothrombotic infarction, n (%)	314 (32.5%)	28 (34.1%)	188 (30.2%)	75 (35.4%)	23 (47.9%)	0.055	0.755	0.993	0.276	0.463
Artery-to-artery embolic stroke, n (%)	227 (23.5%)	15 (18.3%)	154 (24.7%)	50 (23.6%)	8 (16.7%)	0.103	0.999	0.510	0.382	0.877
Cardioembolic stroke, n (%)	150 (15.5%)	20 (24.4%)	107 (17.2%)	20 (9.4%)	3 (6.3%)	0.393	0.525	0.871	0.289	0.489
Embolic stroke of undetermined source, n (%)	120 (12.4%)	15 (18.3%)	80 (12.8%)	23 (10.8%)	2 (4.2%)	0.002†	0.575	0.987	0.591	0.727
Stroke of other determined etiology, n (%)	29 (3.0%)	2 (2.4%)	19 (3.0%)	6 (2.8%)	2 (4.2%)	0.953	0.380	0.034	0.199	0.897
Emergency endovascular treatment, n (%)	90 (9.3%)	12 (14.6%)	58 (9.3%)	9 (0.9%)	1 (2.1%)	0.125	0.429	0.999	0.322	0.372
MRI-PVH grade	0.699±0.802	1.012±0.936	0.717±0.786	0.613±0.779	0.312±0.657	<0.001†	0.032†	0.218	<0.001†	0.028†
MRI-DWMH grade	1.107±0.802	1.402±0.783	1.118±0.791	1.028±0.814	0.812±0.790	<0.001†	0.016†	0.386	0.030†	0.285
MRA stenosis ≥50% or occlusion (+), n (%)	296 (30.7%)	31 (37.8%)	186 (29.9%)	65 (30.7%)	14 (29.2%)	0.531	0.459	0.996	0.999	0.997
Echo ICA stenosis ≥30% (+), n (%)	411 (42.6%)	44 (53.7%)	278 (44.6%)	80 (37.7%)	9 (18.8%)	<0.001†	0.412	0.298	0.003†	0.060
Laboratory blood tests on admission										
Hb (g/L)	140.6±46.1	126.2±19.7	138.0±19.2	145.1±17.0	151.4±21.1	<0.001†	<0.001†	<0.001†	<0.001†	0.031†
BUN (mmol/L)	5.018±2.757	7.097±3.671	6.347±2.590	5.930±2.853	5.426±2.198	<0.001†	0.761	0.001†	0.005†	0.446
Cre (umol/L)	80.21±75.41	77.70±76.47	87.69±64.27	78.23±25.72	75.23±25.72	0.006†	0.009†	0.826	0.881	0.699
Total protein (g/dl)	71.4±5.667	70.45±5.91	71.40±5.72	74.73±5.47	72.08±5.41	0.249	0.616	0.858	0.530	0.868
Albumin (g/dl)	40.07±4.35	37.91±4.84	39.84±4.34	41.37±3.58	40.91±4.97	<0.001†	0.003†	<0.001†	0.311	0.982
Total cholesterol (mmol/L)	5.116±1.107	5.156±1.115	5.004±1.079	5.286±1.048	5.725±1.406	<0.001†	0.652	0.002†	0.002†	0.279
Triglycerides (mmol/L)	1.286±0.777	1.068±0.386	1.365±0.727	1.712±0.876	2.437±1.958	<0.001†	0.002†	<0.001†	<0.001†	0.039†
HDL cholesterol (mmol/L)	1.396±0.416	1.618±0.436	1.405±0.382	1.281±0.353	1.388±0.759	<0.001†	<0.001†	<0.001†	0.086	0.999
LDL cholesterol (mmol/L)	3.234±1.032	3.130±0.940	3.145±1.053	3.434±0.962	3.686±0.969	<0.001†	0.999	<0.001†	0.001†	0.347
HbA1C (%)	6.583±3.020	5.960±0.783	6.573±3.571	6.648±1.624	7.475±1.981	<0.001†	0.088	0.044†	<0.001†	0.003†
NIHSS at discharge (IQR/min-max)	2.0 (1-7/0-37)	5.5 (2-11/0-32)	2.0 (1-7/0-35)	2.0 (0-5/0-37)	1.0 (1-3.25/0-17)	<0.002†	0.003†	0.723	0.021†	0.090
Nasogastric tubefeeding (+), n (%)	66 (6.8%)	9 (11.0%)	49 (7.9%)	7 (3.3%)	1 (2.1%)	0.048†	0.908	0.114	0.473	0.971

MRI: magnetic resonance imaging, PVH: periventricular hyperintensity, DWMH: deep white matter hyperintensity, MRA: magnetic resonance angiography, ICA: internal carotid artery, Hb: hemoglobin, BUN: blood urea nitrogen, Cre: creatinine, HDL: high density lipoprotein, LDL: low density lipoprotein, HbA1c: glycohemoglobin, NIHSS: national institute of health stroke scale, IQR: interquartile range. Dagger indicates statistically significant differences.

Table 2: Characteristics of the participants analyzed with propensity score matching methods

	(a) underweight vs normal weight			(b) normal weight vs overweight			(c) normal weight vs obese			(d) overweight weight vs obese		
	Cohort 1 (n=82)	Cohort 2 (n=82)	p-value	Cohort 2 (n=209)	Cohort 3 (n=209)	p-value	Cohort 2 (n=42)	Cohort 4 (n=42)	p-value	Cohort 3 (n=42)	Cohort 4 (n=42)	p-value
	BMI<18.5	18.5≤BMI<25		18.5≤BMI<25	25≤BMI<30		18.5≤BMI<25	30≤BMI		25≤BMI<30	30≤BMI	
Age (years)	78.91±9.93	78.44±8.80	0.746	68.89±12.15	68.69±12.2	0.866	58.07±12.45	58.36±12.51	0.917	58.60±11.98	58.76±11.84	0.949
Male /Female	37 / 45	34 / 48	0.639	132 / 77	140 / 69	0.413	33 / 9	29 / 13	0.327	30 / 12	28 / 14	0.489
Body Mass Index (kg/m ²)	17.10±1.34	21.95±1.77	<0.001†	22.02±1.79	26.85±1.36	<0.001†	22.69±1.57	33.05±4.59	<0.001†	26.85±1.37	33.17±4.59	<0.001†
Length of hospitalization (days)	21.96±18.24	17.05±12.48	0.054	15.26±10.32	15.94±12.28	0.543	11.98±8.16	14.02±9.24	0.285	14.508±9.35	14.21±9.36	0.889
Risk factor and comorbidity												
Current smoker, n (%)	10 (12.2%)	8 (9.8%)	0.620	64 (30.6%)	52 (24.9%)	0.191	17 (40.5%)	17 (40.5%)	1.000	14 (33.3%)	16 (42.9%)	0.375
History of heart disease†, n (%)	6 (7.3%)	12 (14.6%)	0.136	23 (11.0%)	22 (10.5%)	0.875	3 (7.1%)	3 (7.1%)	1.000	4 (9.5%)	3 (7.1%)	0.697
Current medication												
Hypertension, n (%)	44 (53.7%)	60 (73.2%)	0.009†	133 (63.6%)	163 (78.0%)	0.001†	21 (50.0%)	29 (69.0%)	0.077	32 (76.2%)	29 (69.0%)	0.469
Diabetes mellitus, n (%)	13 (15.9%)	24 (29.3%)	0.040†	41 (19.6%)	65 (31.1%)	0.007†	4 (9.5%)	18 (42.9%)	<0.001†	13 (31.0%)	20 (47.6%)	0.121
Dyslipidemia, n (%)	25 (30.5%)	36 (44.0%)	0.076	84 (40.2%)	114 (54.5%)	0.003†	16 (38.1%)	23 (54.8%)	0.129	27 (64.3%)	22 (52.4%)	0.274
Ischemic stroke subtype												
Lacunar infarction, n (%)	2 (2.4%)	8 (9.8%)	0.051	25 (12.0%)	38 (18.2%)	0.076	6 (14.3%)	10 (23.9%)	0.272	5 (11.9%)	9 (21.4%)	0.247
Atherothrombotic infarction, n (%)	28 (34.1%)	22 (26.8%)	0.251	67 (32.1%)	73 (34.9%)	0.535	11 (26.2%)	21 (50.0%)	0.025†	13 (31.0%)	23 (54.8%)	0.028†
Artery-to-artery embolic stroke, n (%)	15 (18.3%)	15 (18.3%)	1.000	47 (22.5%)	50 (23.9%)	0.729	8 (19.0%)	6 (14.3%)	0.564	11 (26.2%)	6 (14.2%)	0.179
Cardioembolic stroke, n (%)	20 (24.4%)	20 (24.4%)	1.000	31 (14.8%)	20 (9.6%)	0.101	7 (16.7%)	2 (4.7%)	0.079	5 (11.9%)	2 (4.8%)	0.241
Embolic stroke of undetermined source, n (%)	15 (18.3%)	14 (17.1%)	0.839	28 (13.4%)	23 (11.0%)	0.456	7 (16.7%)	1 (2.4%)	0.026†	4 (9.5%)	1 (2.4%)	0.171
Stroke of other determined etiology, n (%)	2 (2.4%)	3 (3.7%)	0.652	11 (5.2%)	5 (2.4%)	0.127	3 (7.1%)	2 (4.7%)	0.649	4 (9.5%)	1 (2.4%)	0.171
Emergency endovascular treatment, n (%)	12 (14.6%)	8 (9.8%)	0.343	22 (10.5%)	19 (9.1%)	0.623	4 (9.5%)	1 (2.4%)	0.171	7 (16.7%)	1 (2.4%)	0.026†
MRI-PVH grade	1.012±0.936	0.829±0.587	0.173	0.622±0.655	0.617±0.673	0.950	0.357±0.544	0.357±0.527	1.000	0.405±0.504	0.333±0.508	0.620
MRI-DWMH grade	1.402±0.783	1.207±0.556	0.098	1.001±0.550	1.029±0.588	0.807	0.738±0.633	0.881±0.545	0.397	0.905±0.646	0.881±0.857	0.895
MRA stenosis ≥50% or occlusion (+), n (%)	31 (37.8%)	25 (30.5%)	0.326	53 (25.3%)	65 (31.1%)	0.193	11 (26.2%)	11 (26.2%)	1.000	17 (40.5%)	10 (23.9%)	0.104
Echo ICA stenosis ≥30% (+), n (%)	44 (53.7%)	42 (51.2%)	0.756	86 (41.1%)	79 (37.8%)	0.485	13 (31.0%)	7 (16.7%)	0.127	12 (28.6%)	7 (16.7%)	0.197
Laboratory blood tests on admission												
Hb (g/L)	126.2±19.7	131.6±16.1	0.058	138.2±19.9	145.3±16.9	<0.001†	142.7±17.0	151.5±21.8	0.043†	150.0±13.2	148.8±20.9	0.751
BUN (mmol/L)	7.097±3.671	6.844±2.899	0.625	16.49±6.54	16.67±7.99	0.796	4.787±1.674	5.401±2.185	0.153	5.766±1.867	5.476±1.553	0.529
Cre (umol/L)	77.70±76.47	83.10±61.88	0.603	76.91±53.92	78.68±25.64	0.611	69.84±22.10	75.14±25.63	0.312	77.79±21.22	76.91±27.40	0.861
Total protein (g/dl)	70.45±5.91	71.40±5.72	0.648	71.14±4.42	71.53±4.31	0.480	71.31±4.47	72.38±4.13	0.360	71.98±3.64	71.90±4.49	0.950
Albumin (g/dl)	37.91±4.84	39.84±4.34	0.156	40.00±3.42	41.38±2.83	0.001†	41.21±2.66	41.21±3.74	1.000	42.12±2.33	40.36±3.88	0.053
Total cholesterol (mmol/L)	5.156±1.115	4.873±1.185	0.115	5.083±1.141	5.276±1.051	0.061	5.232±0.922	5.651±1.222	0.080	5.496±1.044	5.756±1.434	0.344
Triglycerides (mmol/L)	1.068±0.386	1.194±0.872	0.013†	1.355±0.386	1.724±0.766	<0.001†	1.666±1.001	2.217±1.252	0.044†	1.841±0.963	2.398±1.750	0.108
HDL cholesterol (mmol/L)	1.618±0.436	1.424±0.385	0.003†	1.444±0.436	1.275±0.349	<0.001†	1.460±0.402	1.416±0.805	0.752	1.190±0.330	1.425±0.800	0.082
LDL cholesterol (mmol/L)	3.130±0.940	3.009±1.628	0.441	3.156±0.941	3.426±0.966	0.004†	3.186±0.856	3.653±0.935	0.019†	3.664±0.969	3.690±0.975	0.904
HbA1C (%)	5.960±0.783	6.573±3.571	0.002†	6.652±1.494	6.644±1.096	0.984	5.819±0.430	7.452±1.380	<0.001†	6.880±2.040	7.480±1.940	0.169
NIHSS at discharge (IQR/min-max)	5.5 (2-11/0-32)	3.0 (1-7/0-35)	0.234	2.0 (1-5/0-33)	2.0 (1-4/0-37)	0.473	2.0 (1-3/0-21)	1.0 (1-2/0-17)	0.313	2.0 (1-3/0-21)	1.0 (1-2/0-17)	0.313
Nasogastric tubefeeding (+), n (%)	9 (11.0%)	9 (11.0%)	1.000	13 (6.2%)	13 (6.2%)	1.000	2 (7.1%)	1 (2.4%)	0.311	0 (0%)	1 (2.4%)	0.320

Study abbreviations are explained in a footnote to Table 1.

Figure 1

